UPDATE: Wells Fargo Starts MediWound Ltd (MDWD) at Outperform

August 17, 2016 7:20 AM EDT
Get Alerts MDWD Hot Sheet
Price: $5.25 -1.87%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade MDWD Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - August 17, 2016 7:45 AM EDT)

Wells Fargo initiated coverage on MediWound Ltd (NASDAQ: MDWD) with an Outperform rating and a price target of $13-$15. Analyst David Maris highlighted the company's potentially game-changing treatment of burn and wound care.

"We believe MediWound represents a compelling investment opportunity as its products, we believe, have the potential to revolutionize the treatment of burns and chronic wounds if approved," said Maris.

"We believe 1H17 will be pivotal for MediWound, with the shift of its chronic wounds treatment EscharEx into Phase III by year-end 2016 and top-line results expected from the NexoBrid U.S. Phase III in 1H17. NexoBrid is approved for the treatment of burns in Europe, where its launch has been off to a slow start as MediWound works to educate physicians about the paradigm-shifting treatment," added the analyst.

For an analyst ratings summary and ratings history on MediWound Ltd click here. For more ratings news on MediWound Ltd click here.

Shares of MediWound Ltd closed at $6.37 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Wells Fargo, David Maris

Add Your Comment